company background image
ANGO

AngioDynamicsNasdaqGS:ANGO Stock Report

Market Cap

US$1.1b

7D

-4.6%

1Y

89.6%

Updated

26 Nov, 2021

Data

Company Financials +
ANGO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ANGO Stock Overview

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally.

AngioDynamics Competitors

Abbott Laboratories

NYSE:ABT

US$222.6b

Medtronic

NYSE:MDT

US$149.3b

Stryker

NYSE:SYK

US$91.9b

Becton Dickinson

NYSE:BDX

US$69.6b

Price History & Performance

Summary of all time highs, changes and price drops for AngioDynamics
Historical stock prices
Current Share PriceUS$27.22
52 Week HighUS$32.00
52 Week LowUS$13.55
Beta0.86
1 Month Change-3.85%
3 Month Change-3.54%
1 Year Change89.55%
3 Year Change26.66%
5 Year Change65.27%
Change since IPO117.76%

Recent News & Updates

Oct 28
Shareholders May Not Be So Generous With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation And Here's Why

Shareholders May Not Be So Generous With AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Compensation And Here's Why

Despite strong share price growth of 39% for AngioDynamics, Inc. ( NASDAQ:ANGO ) over the last few years, earnings...

Oct 07
Is AngioDynamics (NASDAQ:ANGO) Weighed On By Its Debt Load?

Is AngioDynamics (NASDAQ:ANGO) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Shareholder Returns

ANGOUS Medical EquipmentUS Market
7D-4.6%-2.8%-0.7%
1Y89.6%17.3%24.7%

Return vs Industry: ANGO exceeded the US Medical Equipment industry which returned 17.3% over the past year.

Return vs Market: ANGO exceeded the US Market which returned 24.7% over the past year.

Price Volatility

Is ANGO's price volatile compared to industry and market?
ANGO volatility
ANGO Average Weekly Movement5.6%
Medical Equipment Industry Average Movement7.2%
Market Average Movement6.0%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: ANGO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: ANGO's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1988800Jim Clemmerhttps://www.angiodynamics.com

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and vascular access; and for use in oncology and surgical settings in the United States and internationally. The company provides NanoKnife ablation systems for the surgical ablation of soft tissues; solero microwave tissue ablation systems; and radiofrequency ablation products for ablating solid cancerous or benign tumors. It also offers BioSentry tract sealant systems, IsoLoc Endorectal Balloon's, alatus vaginal balloon packing systems, angiographic catheters, guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits.

AngioDynamics Fundamentals Summary

How do AngioDynamics's earnings and revenue compare to its market cap?
ANGO fundamental statistics
Market CapUS$1.05b
Earnings (TTM)-US$34.25m
Revenue (TTM)US$297.77m

3.5x

P/S Ratio

-30.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ANGO income statement (TTM)
RevenueUS$297.77m
Cost of RevenueUS$136.60m
Gross ProfitUS$161.16m
ExpensesUS$195.42m
Earnings-US$34.25m

Last Reported Earnings

Aug 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.89
Gross Margin54.12%
Net Profit Margin-11.50%
Debt/Equity Ratio5.7%

How did ANGO perform over the long term?

See historical performance and comparison

Valuation

Is AngioDynamics undervalued compared to its fair value and its price relative to the market?

2.41x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: ANGO ($28.85) is trading above our estimate of fair value ($3.65)

Significantly Below Fair Value: ANGO is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: ANGO is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: ANGO is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ANGO's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ANGO is good value based on its PB Ratio (2.6x) compared to the US Medical Equipment industry average (3.9x).


Future Growth

How is AngioDynamics forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

50.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ANGO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ANGO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ANGO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ANGO's revenue (7.6% per year) is forecast to grow slower than the US market (10.1% per year).

High Growth Revenue: ANGO's revenue (7.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ANGO's Return on Equity is forecast to be low in 3 years time (2.3%).


Past Performance

How has AngioDynamics performed over the past 5 years?

-46.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ANGO is currently unprofitable.

Growing Profit Margin: ANGO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ANGO is unprofitable, and losses have increased over the past 5 years at a rate of 46.8% per year.

Accelerating Growth: Unable to compare ANGO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ANGO is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (51.2%).


Return on Equity

High ROE: ANGO has a negative Return on Equity (-7.86%), as it is currently unprofitable.


Financial Health

How is AngioDynamics's financial position?


Financial Position Analysis

Short Term Liabilities: ANGO's short term assets ($131.3M) exceed its short term liabilities ($52.1M).

Long Term Liabilities: ANGO's short term assets ($131.3M) exceed its long term liabilities ($67.7M).


Debt to Equity History and Analysis

Debt Level: ANGO has more cash than its total debt.

Reducing Debt: ANGO's debt to equity ratio has reduced from 23% to 5.7% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable ANGO has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: ANGO is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 24% per year.


Dividend

What is AngioDynamics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ANGO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ANGO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ANGO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ANGO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ANGO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.4yrs

Average management tenure


CEO

Jim Clemmer (57 yo)

5.58yrs

Tenure

US$4,045,913

Compensation

Mr. James C. Clemmer, also known as Jim, has been the Chief Executive Officer, President and a Director of AngioDynamics, Inc. since joining it on April 04, 2016. Mr. Clemmer served as Group President of t...


CEO Compensation Analysis

Compensation vs Market: Jim's total compensation ($USD4.05M) is above average for companies of similar size in the US market ($USD2.24M).

Compensation vs Earnings: Jim's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ANGO's management team is considered experienced (3.4 years average tenure).


Board Members

Experienced Board: ANGO's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ANGO insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AngioDynamics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: AngioDynamics, Inc.
  • Ticker: ANGO
  • Exchange: NasdaqGS
  • Founded: 1988
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$1.052b
  • Shares outstanding: 38.65m
  • Website: https://www.angiodynamics.com

Number of Employees


Location

  • AngioDynamics, Inc.
  • 14 Plaza Drive
  • Latham
  • New York
  • 12110
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 21:21
End of Day Share Price2021/11/26 00:00
Earnings2021/08/31
Annual Earnings2021/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.